Ļć½¶ŹÓʵ

Harsh R. Shah
( out of 90 reviews )

Harsh R. Shah, DO

Languages spoken: Gujarati, Hindi, English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Languages Spoken: English, Hindi, Gujarati

    Harsh Shah DO is an Assistant Professor of Medicine in the Division of Hematology at the Huntsman Cancer Center, Ļć½¶ŹÓʵ of Utah.

    Dr. Shahā€™s clinical expertise is in treatment of various lymphomas, such as Hodgkinā€™s Lymphoma, T-cell Lymphomas, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, CLL, etc. He has a research interest in immunotherapy resistance pathways in treatment of Hodgkin Lymphomas, particularly the role of Tumor Associated Macrophages. He is also interested in outcomes research and novel educational strategies for medical students, residents, and fellows.

    He completed his internal medicine training at Indiana Ļć½¶ŹÓʵ in Indianapolis and hematology and oncology fellowship at Karmanos Cancer Institute/Wayne State Ļć½¶ŹÓʵ in Detroit, Michigan. He is certified in both hematology and oncology.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 90 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 04, 2024
    HUNTSMAN CANCER CENTER

    An empathetic and wonderful human being

    October 03, 2024
    HUNTSMAN CANCER CENTER

    Trust him with my life! Great bedside manner!

    September 26, 2024
    HUNTSMAN CANCER CENTER

    Smart, precessional, answers questions. Remembers things about us. He's great!Āæ

    September 06, 2024
    HUNTSMAN CANCER CENTER

    Dr Shah is great.

    September 01, 2024
    HUNTSMAN CANCER CENTER

    excellent and caring. Makes everything very clear and understandable.

    July 12, 2024
    HUNTSMAN CANCER CENTER

    We are truly fortunate to have Dr. Shah in our community. Will forever be grateful for his care, knowledge, competency and commitment to a cure and care. THank you!

    June 23, 2024
    HUNTSMAN CANCER CENTER

    Clear straightforward communication style. Willing to share uncertainties about future treatment plans

    May 19, 2024
    HUNTSMAN CANCER CENTER

    Very understanding person, Dr. Easy to talk to and he takes time to listen and explain what is going on.

    May 18, 2024
    HUNTSMAN CANCER CENTER

    Dr. Shah is a very caring physician with a very good bedside manner.

    See More Patient Comments

  • Languages Spoken: English, Hindi, Gujarati

    Harsh Shah DO is an Assistant Professor of Medicine in the Division of Hematology at the Huntsman Cancer Center, Ļć½¶ŹÓʵ of Utah.

    Dr. Shahā€™s clinical expertise is in treatment of various lymphomas, such as Hodgkinā€™s Lymphoma, T-cell Lymphomas, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, CLL, etc. He has a research interest in immunotherapy resistance pathways in treatment of Hodgkin Lymphomas, particularly the role of Tumor Associated Macrophages. He is also interested in outcomes research and novel educational strategies for medical students, residents, and fellows.

    He completed his internal medicine training at Indiana Ļć½¶ŹÓʵ in Indianapolis and hematology and oncology fellowship at Karmanos Cancer Institute/Wayne State Ļć½¶ŹÓʵ in Detroit, Michigan. He is certified in both hematology and oncology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology-Oncology - Karmanos Cancer Institute - Wayne State Ļć½¶ŹÓʵ Fellow
    Internal Medicine - Indiana Ļć½¶ŹÓʵ School of Medicine Resident
    Professional Medical Osteopathic Medicine - Kirksville College of Osteopathic Medicine - AT Still Ļć½¶ŹÓʵ of Health Sciences D.O.
    Biomedical Engineering - Ļć½¶ŹÓʵ of Michigan M.S.E.
    Undergraduate Biomedical Engineering - Ļć½¶ŹÓʵ of Michigan B.S.E.

    Selected Publications

    Journal Article

    1. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. ()
    2. Desai SH, Spinner MA, Evens AM, Sykorova A, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Chang C, Michalka J, Ansell SM, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Wagner-Johnston N, Arai S, Nowakowski GS, Mocikova H, Jagadeesh D, Blum KA, Diefenbach C, Iyengar S, Rappazzo KC, Baidoun F, Choi Y, Prochazka V, Advani RH, Micallef I (2023). Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Adv, 7(23), 7295-7303. ()
    3. Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open, 6(6), e2316642. ()
    4. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica, 108(11), 3025-3032. ()
    5. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Ramakrishnan Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL (2023). Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma. Clin Cancer Res. ()
    6. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40ā€‰years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. ()
    7. Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN (2023). Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. ()
    8. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 1-8. ()
    9. Shah H, Jang H, Kim S, Halwani AS (2022). A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br J Haematol, 200(5), 579-586. ()
    10. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. ()
    11. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2022). Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. Clin Cancer Res, 28(15), 3242-3247. ()
    12. Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A (2021). Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leuk Lymphoma, 63(4), 813-820. ()
    13. Shah HR, Stephens DM (2021). Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program, 2021(1), 68-75. ()
    14. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 139, 413-423. ()
    15. Shah H, Stephens D, Seymour J, Maddocks K (2021). Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. Am Soc Clin Oncol Educ Book, 41, 1-18. ()
    16. Vaishampayan U, Shah H, Asad MF, Shi D, Dickow B, Suisham S, Domina J, Cher ML, Samantray J, Aoun HD (2020). Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. J Kidney Cancer VHL, 7(4), 1-7. ()
    17. Shah H, Kim S, Singh P, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Deol A (2019). Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts. Am J Hematol, 95(2), 198-204. ()
    18. Shah H, Vaishampayan U (2018). Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. Target Oncol, 13(6), 679-689. ()
    19. Shah H, Bradford C, Sayar H (2015). Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis. Case Rep Hematol, 2015, 826894. ()

    Review

    1. Salem AE, Shah HR, Covington MF, Koppula BR, Fine GC, Wiggins RH, Hoffman JM, Morton KA (2022). PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies. [Review]. Cancers (Basel), 14(23). ()

    Case Report

    1. Shah H, McPherson K, Mansour A, Ramirez-Santrich C, Nassiri M, Shahda S (2016). Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia. Clin Colorectal Cancer, 15(4), e235-e239. ()

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. ()
    2. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. [Letter to the editor]. J Hematol Oncol, 16(1), 111. ()
    3. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. ()
    4. Shah H, Kim S, Klimecki S, Charlson K, Uberti J, Schiffer CA, Fiala MA, Seymour E (2022). Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. [Letter to the editor]. Bone Marrow Transplant, 57, 1213-1215. ()